Abstract
Ronald Siyi Lu, Candela Díaz-Cañestro, Erfei Song, Xi Jia, Cunchuan Wang, Cynthia Cheung, Aimin Xu
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
2022
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
10.1002/hep.29367 · 2018
10.1002/hep.23594
10.1002/hep.23594
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
10.3748/wjg.v20.i2.475 · 2014
10.1146/annurev-pathol-020117-043617
10.1146/annurev-pathol-020117-043617
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
10.1016/j.jhep.2020.03.039 · 2020
A multi-society Delphi consensus statement on new fatty liver disease nomenclature
2023
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature reviews Gastroenterology &
2021
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
10.1097/hep.0000000000000542 · 2024
Metabolomics discloses a new non-invasive method for the diagnosis and prognosis of patients with alcoholic hepatitis
10.5604/01.3001.0012.7906 · 2019
Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts
10.1002/hep4.1188 · 2018
Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis
10.1016/j.jhep.2021.04.013 · 2021
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease
10.1097/mcg.0b013e3181dd1348 · 2011
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
10.1002/hep.27173 · 2014
Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts
10.1002/hep4.1188 · 2018
The use of BMI and waist circumference as surrogates of body fat differs by ethnicity
10.1038/oby.2007.334 · 2007
Visceral fat: a key mediator of steatohepatitis in metabolic liver disease
10.1002/hep.22350 · 2008
10.1016/j.jhep.2021.09.024
10.1016/j.jhep.2021.09.024
Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis
10.1002/oby.22627 · 2019
PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer
10.1159/000282095 · 2010
Omega-3 fatty acids and metabolic partitioning of fatty acids within the liver in the context of nonalcoholic fatty liver disease
2022
10.1016/j.freeradbiomed.2020.02.025
10.1016/j.freeradbiomed.2020.02.025
Elevated citrate levels in non-alcoholic fatty liver disease: the potential of citrate to promote radical production
10.1016/j.febslet.2013.06.019 · 2013
Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis
10.1002/hep.25630 · 2012
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance
10.1002/hep.29465 · 2018
Branched chain amino acids: Passive biomarkers or the key to the pathogenesis of cardiometabolic diseases?
10.17219/acem/104542 · 2019
N-Acyl taurines trigger insulin secretion by increasing calcium flux in pancreatic beta-cells
10.1016/j.bbrc.2012.11.026 · 2013
Metabolomics analysis identifies different metabotypes of asthma severity
10.1183/13993003.01740-2016 · 2017
Medium-chain fatty acids suppress lipotoxicity-induced hepatic fibrosis via the immunomodulating receptor GPR84
10.1172/jci.insight.165469 · 2023
Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease
10.1053/j.gastro.2013.11.049 · 2014
The plasma lipidomic signature of nonalcoholic steatohepatitis
10.1002/hep.23229 · 2009
Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis in mice
10.1002/hep.29039 · 2017
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
10.1007/s00125-013-2981-2 · 2013
Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid
2017
No additional external references are available.